Trials / Terminated
TerminatedNCT00874497
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
A Multi-center, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Pharmacodynamics, Efficacy and Safety of 50 mg Tetomilast Administered as Oral Tablets in Patients With Chronic Obstructive Pulmonary Disease Associated With Emphysema THIS STUDY IS CLOSED TO ENROLLMENT AND NEW SITES
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tetomilast | Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years. |
| DRUG | placebo | Placebo for 104 weeks (2 years) |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2015-07-01
- Completion
- 2015-08-01
- First posted
- 2009-04-02
- Last updated
- 2017-04-17
- Results posted
- 2017-04-17
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00874497. Inclusion in this directory is not an endorsement.